Outputs (2)

The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population (2025)
Journal Article
Alawadi, A. A., Vijay, A., Grove, J. I., Taylor, M. A., & Aithal, G. P. (2025). The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population. Metabolism Open, 100351. https://doi.org/10.1016/j.metop.2025.100351

Background
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) affects up to one in five people in the UK, with persistent overeating and a sedentary lifestyle being significant risk factors. Exploring dietary patterns at a food level i... Read More about The development of a food-group, tree classification method and its use in exploring dietary associations with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other health-related outcomes in a UK Population.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K. M., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.